What question did this study set out to answer?

The aim is to determine if thiotepa inclusion in myeloablative regimens enhances donor chimerism in children with immune disorders.

April 17, 2026

Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders

Key Points

The aim is to determine if thiotepa inclusion in myeloablative regimens enhances donor chimerism in children with immune disorders.
Evaluated the impact of thiotepa in myeloablative regimens
Targeted children with inborn errors of immunity and metabolic disorders
Followed donor chimerism levels post-treatment
Inclusion of thiotepa significantly enhanced donor chimerism
Higher chimerism levels correlated with improved outcomes
Children treated showed better immune response compared to those without thiotepa

Abstract

Original data are available upon reasonable request from the corresponding author, Caitlyn McComb. Email: email protected. Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Inclusion of Thiotepa in Myeloablative Regimens Improves Donor Chimerism in Children with Inborn Errors of Immunity or Inherited Metabolic Disorders

Key Points

Abstract

Cite This Study